Beverly Hills, CA, United States of America

Aya Jakobovits

This inventor holds 191 USPTO granted patents and 34 published patent applications, plus 18 CIPO patents and 31 EPO patents, primarily in Cancer Immunotherapy (CPC class A61K2039-505). Top assignees: Agensys, Inc., Abgenix, Inc., Adicet Therapeutics, Inc.. Active years: 1996-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Aya Jakobovits. Retrieved from https://idiyas.com/inventor/aya-jakobovits

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 191 (Patent Applications = 34)

% Patents Active = 48.7

CIPO Patents = 18 (Patent Applications = 14)

EPO Patents = 31 (Patent Applications = 34)

Average Co-Inventor Count = 5.4

ph-index = 24

Forward Citations = 7,444(Granted Patents)

Forward Citations (Not Self Cited) = 7,209(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Menlo Parl, CA (US) (2001)
Los Angeles, CA (US) (2006)
Menlo Park, CA (US) (1996 - 2014)
Beverly Hills, CA (US) (2001 - 2022)
South San Francisco, CA (US) (2014 - 2023)

Company Filing History:

Adicet Therapeutics, Inc.

Seattle Genetics, Inc.

patents

7. 4 out of 16,035

University of California

16. 6 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1996-2026

Loading Chart...

Areas of Expertise:

Engineered T-cells

Gamma Delta T-cells

Antibody Drug Conjugates

HLA-A2 Binding

STEAP-1 Proteins

Nucleic Acids

Cancer Detection

Prostate Stem Cell Antigen

Tumor Associated Proteins

Cancer Treatment

Immunoconjugates

191 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12698340 - COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED GAMMA DELTA T-CELLS FOR TREATMENT OF SOLID TUMORS (2026-08-04),

2. 12692319 - COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED GAMMA DELTA T-CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS (2026-07-28),

3. 12371663 - Engineered γδ T-cells (2025-07-29),

4. 12364714 - Methods for selective expansion of gamma delta t-cell populations and compositions thereof (2025-07-22),

5. 12221480 - Methods for selective expansion of delta-3 gamma delta T-cell populations and compositions thereof (2025-02-11),

6. 11559582 - Antibody drug conjugates (ADC) that bind to 191P4D12 proteins (2023-01-24),

7. 11485785 - Antibodies capable of binding HLA-A2/TyrD in an HLA restricted manner and uses thereof (2022-11-01),

8. 11401347 - Antibodies and molecules derived therefrom that bind to STEAP-1 proteins (2022-08-02),

9. 11299708 - Methods for selective expansion of γδ T-cell populations and compositions thereof (2022-04-12),

10. 11135245 - Engineered γδ T-cells (2021-10-05),

11. 10894090 - Antibody drug conjugates (ADC) that bind to 191P4D12 proteins (2021-01-19),

12. RE48389 - Antibody drug conjugates (ADC) that bind to 191P4D12 proteins (2021-01-11),

13. 10597463 - Antibodies and molecules derived therefrom that bind to STEAP-1 proteins (2020-03-24),

14. 9962454 - Antibody drug conjugates (ADC) that bind to 191P4D12 proteins (2018-05-08),

15. 9617346 - Antibodies and molecules derived therefrom that bind to STEAP-1 proteins (2017-04-11),

Title: Aya Jakobovits: Pioneering Innovations in Cancer Therapeutics

Introduction:

Aya Jakobovits, based in Beverly Hills, CA, is a highly accomplished inventor and researcher specializing in the development of innovative pharmaceutical solutions for cancer treatment. With an impressive portfolio of 185 patents, Jakobovits has made significant contributions to the field of antibody drug conjugates (ADC) and has played a pivotal role in advancing cancer therapeutics. This article highlights Jakobovits' latest patents, career highlights, collaborations, and his impact in the field of cancer research and treatment.

Latest Patents:

Among Jakobovits' recent patents, two notable inventions stand out. The first relates to Antibody Drug Conjugates (ADCs) that bind to 191P4D12 proteins, which are associated with tissue-specific expression in normal adult tissue and are aberrantly expressed in various cancers. By targeting 191P4D12 proteins, these ADCs present an innovative therapeutic composition for combating cancer.

His second patent involves the development of antibodies capable of binding to HLA-A2/Tyrosinase (TyrD), specifically targeting the HLA-A2/TyrD369-377 region. These antibodies have demonstrated the potential to be harnessed for cancer treatment, showing great promise in the field of immunotherapy.

Career Highlights:

Throughout his career, Jakobovits has made significant contributions to the biopharmaceutical industry. He has held key positions in leading companies such as Agensys, Inc. and Abgenix, Inc., where his expertise in antibody-based therapies and drug development was instrumental in advancing research and development efforts.

Collaborations:

Jakobovits has collaborated with renowned researchers and scientists in the field of oncology. Notably, he has worked closely with Arthur B Raitano and Pia M Challita-Eid, both esteemed professionals in the pharmaceutical industry. These collaborations have fostered innovation and knowledge sharing, contributing to the development of groundbreaking therapies for cancer.

Conclusion:

Aya Jakobovits is a distinguished figure in the realm of cancer research and treatment, with an extensive patent portfolio and remarkable contributions to the field. His inventive work, particularly in the realm of Antibody Drug Conjugates (ADCs) and the development of targeted antibodies, is helping pave the way for more effective cancer therapies. The impact of Jakobovits' inventions extends beyond patents, as they hold significant potential to improve the lives of cancer patients worldwide, bringing hope and progress to the fight against this devastating disease.

Disclaimer: At IDiyas.com, we provide information about inventors, patents, and innovations. The content of this article is based on publicly available data and may not reflect the full scope of Aya Jakobovits' contributions to the industry. For more accurate and detailed information, please refer to official publications and reliable sources.

Profile summary based on public USPTO records.